FDA Greenlights Neurocrine Biosciences’ (NBIX) VMAT2 Inhibitor INGREZZA; Novan (NOVN) Soars on Athlete’s Foot Trial Data


Shares of Neurocrine Biosciences, Inc. (Nasdaq:NBIX) climbed more than 20% in after-hours trading Tuesday as the U.S. Food and Drug Administration (FDA) gave green light to its selective vesicular monoamine transporter 2 (VMAT2) inhibitor INGREZZA (valbenazine) capsules to treat adults with tardive dyskinesia, a neurological disorder marked by involuntary movements of the jaw, lips and tongue.

NBIX stock finished the regular session in positive territory by 2.90% (or +$1.17) at $41.48 with a total volume of 2.48M shares traded, representing a large increase in activity versus its average volume (3m) of 1.04M shares.

Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders, has 87.11M shares outstanding and NBIX stock 52-week range is between $37.35and $55.15 per share. At close on Tuesday, the biotechnology company had a market capitalization of $3.61B



Novan Inc. (Nasdaq:NOVN) shares soared over 40% in pre-market trade Wednesday after the clinical-stage drug development company said that data from a mid-stage clinical trial showed that its broad-spectrum antifungal gel SB208 performed better than vehicle in treating tinea pedis (or athlete’s foot), confirming the fungicidal activity of nitric oxide.

NOVN stock closed at $5.20, down $0.24 (or -4.41%) on Tuesday’s trading session.

Novan, which focuses on the development and commercialization of nitric oxide-based therapies in dermatology, has 15.97M shares outstanding, market capitalization (intraday) of $83.04M and NOVN stock one-year range is from $3.52 to $30.90 per share.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/